Cytochroma Seeks To Bring Advance Over Hectorol, Zemplar To Market For CKD
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II candidate CTA018 is intended as safer alternative to existing hormone replacement therapies for vitamin D insufficiency.